Skip to main content
. 2013 Nov 15;44(1):17–26. doi: 10.3892/ijo.2013.2179

Figure 3.

Figure 3.

Kaplan-Meier survival estimate. (A) Progression-free survival of c.35 G>A KRAS mutant patients versus KRAS wild-type patients; (B) Overall survival of c.35 G>A KRAS mutant patients versus KRAS wild-type patients; (C) Progression-free survival c.35 G>A KRAS mutant patients versus other KRAS mutant patients; (D) Overall survival c.35 G>A KRAS mutant patients versus other KRAS mutant patients; (E) Progression-free survival, other KRAS mutant patients versus KRAS wild-type patients; (F) Overall survival, other KRAS mutant patients versus KRAS wild-type patients; (G) Progression-free survival, c.35 G>A KRAS mutant patients versus other KRAS mutant plus KRAS wild-type patients; (H) Overall survival, c.35 G>A KRAS mutant patients versus other KRAS mutant plus KRAS wild-type patients.